Ozempic vs Wegovy vs Mounjaro: Which GLP-1 Is Right for You in India?

If you're researching medical weight loss in India in 2026, three names dominate the conversation: Ozempic, Wegovy, and Mounjaro. They're related but not interchangeable. The differences matter — for what they're approved to treat, how much weight you can expect to lose, what they cost in India, and what your doctor will prescribe to you.

This is the side-by-side, written for patients trying to make a real decision.

What they actually are

Drug	Molecule	Mechanism	Approved indication
Ozempic	Semaglutide 0.25 – 2 mg	GLP-1 receptor agonist	Type 2 diabetes
Wegovy	Semaglutide 2.4 mg	GLP-1 receptor agonist	Chronic weight management
Mounjaro	Tirzepatide 2.5 – 15 mg	Dual GIP + GLP-1 agonist	Type 2 diabetes (weight indication in some markets)

So Ozempic and Wegovy are the same molecule (semaglutide), at different doses, for different indications. Mounjaro is a different molecule (tirzepatide) and works on two hormone pathways instead of one, which is partly why its weight-loss outcomes are larger in head-to-head trials.

How effective is each one?

Average weight loss over ~68 – 72 weeks, in clinical trials:

Drug	Average body weight loss
Ozempic 1 mg	~6 – 7% (diabetes trials)
Ozempic 2 mg	~10 – 12% (obesity sub-analyses)
Wegovy 2.4 mg	~14 – 17% (STEP trials)
Mounjaro 5 mg	~15% (SURMOUNT-1)
Mounjaro 15 mg	~21 – 22% (SURMOUNT-1)

Mounjaro at the highest dose currently has the largest average weight-loss outcome of any approved injectable. Wegovy is close behind. Ozempic — at the doses commonly used for diabetes — produces less weight loss because that isn't its primary purpose.

The honest caveat: these are trial averages. Individuals vary widely. A small percentage of people lose dramatically more; another small percentage lose little. Your starting BMI, adherence, diet, sleep, and activity all matter.

India availability in 2026

• Ozempic — widely available through hospital pharmacies and licensed chemists across major Indian cities. Prescribed for type 2 diabetes and, off-label, for weight management.
• Wegovy — being rolled out by Novo Nordisk through authorized pharmacies, metros first.
• Mounjaro — Eli Lilly has begun the Indian launch through authorized channels, but availability is more limited than semaglutide.

In all three cases, prescription is mandatory. Buying any of these from unverified online sources, social media DMs, or "imports without a prescription" is illegal and dangerous — cold chain failure or outright counterfeit is common.

India pricing snapshot (current, May 2026)

Drug	Approx. monthly cost
Ozempic 1 mg	₹12,000 – ₹16,000
Ozempic 2 mg	₹15,000 – ₹18,000
Wegovy 2.4 mg (post Nov 2025 price cut)	₹15,500 – ₹16,400
Generic semaglutide (post Mar 2026 patent expiry)	₹3,000 – ₹6,000
Mounjaro KwikPen 5 mg	₹15,000 – ₹17,500
Mounjaro KwikPen 15 mg	₹26,000 – ₹27,500
Yurpeak (Cipla tirzepatide)	similar to Mounjaro

Two recent shifts that materially change this picture:

1. Novo Nordisk cut Wegovy's price by 37% in November 2025 — bringing the maintenance dose down from ₹26,000+ to under ₹16,400.
2. Semaglutide's Indian patent expired March 20, 2026 — at least 5 Indian generic manufacturers (Cipla, Sun Pharma, Dr Reddy's, Lupin, Biocon) launched semaglutide generics at 60 – 80% lower than branded Wegovy.

Tirzepatide (Mounjaro) is still patent-protected, so there are no legal generics yet.

These are pharmacy-direct costs and shift with supply. They exclude the consultation, lab work, and monitoring that you legally and clinically need on top.

Side effect profile

All three share the GLP-1 side-effect profile: nausea, constipation or diarrhoea, mild reflux, reduced appetite (intended), and occasional fatigue. These are dose-dependent and usually settle within 4 – 8 weeks as your body adjusts.

Mounjaro's dual mechanism produces a slightly different profile — some patients report less nausea, others report more. There's no universal winner; your individual response is what matters.

Rare but serious risks (all three): acute pancreatitis, gallbladder disease, severe hypoglycaemia in patients on insulin or sulfonylureas, and theoretical thyroid risk. This is why ongoing medical supervision isn't optional.

How a doctor chooses for you

In an Indian clinical setting, here's roughly how the decision flows:

1. Type 2 diabetes + weight management goal → Ozempic or Mounjaro (both indicated for diabetes; Mounjaro often produces more weight loss). Wegovy is not the right call here.
2. Obesity (BMI ≥ 30), no diabetes → Wegovy is the most directly indicated. Mounjaro is increasingly used off-label/on-label depending on market.
3. Overweight (BMI ≥ 27) with at least one weight-related comorbidity → Wegovy or Mounjaro, with shared decision-making about cost and tolerability.
4. Cost-sensitive, already responding to lifestyle → Lower-dose Ozempic may be enough, supervised closely.
5. Prior poor tolerability on semaglutide → Mounjaro may be considered if you couldn't tolerate Wegovy/Ozempic.
6. Contraindications (MEN2, medullary thyroid carcinoma history, pregnancy, severe GI disease) → None of the three.

A 30-minute video consultation with a doctor who has reviewed your blood work answers this question faster and more safely than any blog post can.

What you actually pay over 3 months

A realistic budget for 3 months of medical weight management in India:

Line item	Range
Drug (Ozempic 1 mg)	₹36,000 – ₹48,000
Drug (Wegovy, titrated)	₹30,000 – ₹55,000
Drug (Mounjaro, titrated)	₹30,000 – ₹55,000
Initial consultation	₹1,500 – ₹3,000
Blood work	₹2,500 – ₹5,000
Follow-up consultations (×2 – 3)	₹3,000 – ₹6,000
Nutrition support	varies
Total piecemeal	₹35,000 – ₹65,000

Stride's 3-Month Early Edition is ₹9,999 (regular ₹23,999). It bundles assessment + at-home blood test + monthly doctor video consultations + GLP-1 medication delivery when clinically appropriate + nutrition support + continuous monitoring. One-time payment, no auto-renewal.

What Stride prescribes and why

Stride doesn't pick "one drug for everyone." Your prescribing clinician evaluates your gender, age, BMI, history, conditions, and openness to medication, then chooses the GLP-1 that fits — Ozempic for some patients, Wegovy for others, Mounjaro where it's appropriate and available. If GLP-1s are not the right call for you, your clinician will say so during the consultation.

Frequently asked questions

Which is the strongest for weight loss — Ozempic, Wegovy, or Mounjaro? Average trial outcomes: Mounjaro 15 mg (~21%), Wegovy 2.4 mg (~15%), Ozempic 2 mg (~10%). Individual response varies.

Can I switch from Ozempic to Wegovy? Yes — and it's the common path for patients who started on Ozempic off-label for weight loss. Your doctor will titrate you from the Ozempic dose to a Wegovy dose, typically without re-starting at the lowest step.

Are Ozempic and Wegovy the same medicine? Same molecule (semaglutide). Different dose, different approved indication. Wegovy goes higher (2.4 mg) and is licensed specifically for weight management.

Is Mounjaro available in India? Yes — Eli Lilly has launched in India through authorized pharmacy channels. Availability is improving but more limited than semaglutide.

Do all three need a prescription? Yes. All three are prescription-only and require ongoing medical supervision. Buying any of them without a prescription is illegal in India and unsafe.

Will insurance cover any of these? Most Indian retail health insurance does not cover obesity medications. Some corporate or premium policies may cover them when prescribed for diabetes. Check your specific policy.

How long do I need to stay on a GLP-1? This is an active research area. Stopping abruptly often leads to weight regain; many patients use these medications long-term, similar to medications for hypertension or cholesterol. Stride structures plans in 3-month blocks and reassesses with you.

Ready to find out which one is right for you?

Take the 60-second assessment. An Indian-licensed clinician reviews your responses + blood work + goals, and recommends the GLP-1 that fits — or tells you if a medication isn't the right approach at all.

Check your eligibility